Latest News

Global clinical trial of 40,000+ healthcare workers begins to test in UK if chloroquine and hydroxychloroquine can prevent COVID-19

Global clinical trial of 40,000+ healthcare workers begins to test in UK if chloroquine and hydroxychloroquine can prevent COVID-19

Posted 21/05/2020

A global study to test if either chloroquine or hydroxychloroquine can prevent COVID-19 in vital frontline healthcare workers will open to UK participants at hospital sites in Brighton and Oxford today.  Led by the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok, Thailand, the COPCOV study is a double-blind, randomised, placebo-controlled trial that will enrol 40,000+ frontline healthcare workers and staff from Europe, Africa, Asia and South America who have close contact with patients with COVID-19 to determine definitively if chloroquine and hydroxychloroquine are effective in preventing COVID-19.  “COVID-19 is a major risk for frontline healthcare workers around the world,” said COPCOV Co-Principal Investigator Professor Sir Nicholas White

How to set up a trial in nine days

How to set up a trial in nine days

Posted 20/05/2020

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial has recruited more than 10,000 patients in 176 hospitals in just two months - truly incredible figures for that timescale, making it the fastest ever recruiting individually randomised controlled trial. From conception to launch took just nine days! The trial is being co-led by NDM's Professor Peter Horby  and Professor Martin Landray from the Nuffield Department of Population Health (NDPH), and is testing existing drugs, all with well-known side effects and confirmed safety, on hospital inpatients with suspected or confirmed COVID-19.

Prof Xin Lu honoured by the Royal Society

Prof Xin Lu honoured by the Royal Society

Posted 13/05/2020

The Royal Society, the UK’s distinguished academy of science, has announced the election of 62 new Fellows and Foreign Members, which now includes Professor Xin Lu FMedSci FRS 
Xin Lu is a cancer biologist distinguished by her contributions to understanding cellular pathways that control cell fate in development and disease, particularly cancer. She has a long-standing interest in how to selectively kill cancer cells, and her major research advances have provided insights into how p53, the most mutated or inactivated tumour suppressor in human cancers, can make life or death decisions for a cell.

Chan Zuckerberg Initiative awards funding to Oxford team to support inflammation research

Chan Zuckerberg Initiative awards funding to Oxford team to support inflammation research

Posted 01/05/2020

NDM's Dr Anita Milicic from the Jenner Institute, Old Road Campus Research Buillding and Dr Calliope Dendrou from the Wellcome Centre for Human Genetics, are part of a group with Professor Mark Coles from the Kennedy Institute who have received a share of $14 million in funding from the Chan Zuckerberg Initiative as one of 29 projects that will explore emerging ideas regarding the role of inflammation in disease.  The Chan Zuckerberg Initiative (CZI) was founded by Dr. Priscilla Chan and Mark Zuckerberg in 2015, to leverage technology to help solve some of the world’s toughest challenges. These grants build on CZI’s work in single-cell biology supporting the Human Cell Atlas, a fundamental reference for health and disease.

Landmark partnership announced for development of COVID-19 vaccine

Landmark partnership announced for development of COVID-19 vaccine

Posted 30/04/2020
The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.  It is the first such partnership to be formed since the Government launched its dedicated Vaccines Taskforce to help find, test and deliver a new coronavirus vaccine just two weeks ago.  It also comes alongside £20 million Government funding for Oxford University’s vaccine research and support for the institution’s clinical trials.
Digital contact tracing can slow or even stop coronavirus transmission and ease us out of lockdown

Digital contact tracing can slow or even stop coronavirus transmission and ease us out of lockdown

Posted 23/04/2020

A team from NDM's Big Data Institute is sharing an epidemiological model to help configure a contact tracing app for coronavirus. The model offers several safe configurations to introduce an app and a framework to optimise the app after it is released. The simulations confirm that if around half the total population use the app, alongside other interventions, it has the potential to stop the epidemic and help to keep countries out of lockdown. These research efforts are supporting several European projects including the UK’s national programme led by NHSX, a joint unit comprised of teams from NHS England and the Department of Health & Social Care.

The RECOVERY Trial has recruited 1000 patients in 15 days

The RECOVERY Trial has recruited 1000 patients in 15 days

Posted 07/04/2020

The world’s largest randomised clinical trial of potential coronavirus treatments is well underway in the UK as part of the race to find a treatment. A number of promising treatments are being tested and, if the science supports it, will be given to NHS patients as quickly as possible.  The trial is being coordinated by NDM's Peter Horby, Professor of Emerging Infectious Diseases and Global Health and Martin Landray, Professor of Medicine and Epidemiology at the Nuffield Department of Population Health.

Controlling coronavirus transmission using a mobile app to trace close proximity contacts

Controlling coronavirus transmission using a mobile app to trace close proximity contacts

Posted 31/03/2020

A team of medical researchers and bioethicists at Oxford University has published results today in Science that further our understanding of coronavirus transmission.  Professor Christophe Fraser from the Big Data Institute, Nuffield Department of Medicine, a lead author on the Science paper explains, “We need a mobile contact tracing app to urgently support health services to control coronavirus transmission, target interventions and keep people safe". 

Oxford's COVID-19 research receives government funding

Oxford's COVID-19 research receives government funding

Posted 24/03/2020
The three projects include work on an effective vaccine, enabling pre-clinical and clinical vaccine trials, as well as supporting researchers to develop manufacturing processes to produce a vaccine at a million-dose scale. Another project will examine how existing treatments could be repurposed to treat coronavirus: Professor Sarah Gilbert, £2.2 million for vaccine development and trials; Professor Peter Horby - £2.1 million for research into the effectiveness of current drugs on COVID-19 and Dr Sandy Douglas – £0.4 million, research into vaccine manufacturing capabilities.
First patients enrolled in new clinical trial of possible COVID-19 treatments

First patients enrolled in new clinical trial of possible COVID-19 treatments

Posted 23/03/2020
There are currently no specific treatments for COVID-19. It is possible that some existing drugs usually used for other conditions may have some benefits – but they may not. The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial will provide doctors and the health service with information they need to determine which treatments should be used. NDM's Prof Peter Horby, Professor of Emerging Infectious Diseases and Global Health and Chief Investigator discusses the trial in this short interview.

If you have news or events that you would like to be added to this website, please email us details. If possible, please include a picture and links to further information.